ChemicalBook Product Catalog Pharmaceutical intermediates Bulk Drug Intermediates PROSTAGLANDIN J2

PROSTAGLANDIN J2

Product NamePROSTAGLANDIN J2
CAS60203-57-8
MFC20H30O4
MW334.45
EINECS201-185-2
MOL File60203-57-8.mol

Chemical Properties

Boiling point	521.7±50.0 °C(Predicted)
Density	1.103±0.06 g/cm3(Predicted)
storage temp.	−20°C
solubility	DMF: >100 mg/ml (from PGD2); DMSO: >50 mg/ml (from PGD2); Ethanol: >75 mg/ml (from PGD2); PBS pH 7.2: >2.7 mg/ml (from 15-deoxy-.DEL
pka	4.75±0.10(Predicted)
form	Liquid
color	Colorless to light yellow

Safety Information

Hazard Codes	Xn,Xi,F
Risk Statements	20/21/22-36/37/38-67-66-36-11
Safety Statements	26-36-33-29-16

Usage And Synthesis

Description

Prostaglandin J₂ (PGJ₂) is formed from PGD₂ by the elimination of the C-9 hydroxyl group, a process which is accelerated by the presence of albumin. PGJ₂ inhibits platelet aggregation with an IC₅₀ of about 5-10 nM. PGJ₂ has antimitotic and antiproliferative effects on a variety of cultured normal cells and tumor cell lines. However, this activity has been attributed to further metabolites of PGJ₂ and not the parent compound itself.

Uses

PGJ2 (Prostaglandin J2) is a Prostaglandin D2 metabolite that has shown potent anti-neoplastic and antiviral activity.

Definition

ChEBI: A member of the class of prostaglandins J that consists of prosta-5,9,13-trien-1-oic acid substituted by an oxo group at position 11 and a hydroxy group at position 15 (the 5Z,13E,15S stereoisomer).

in vivo

Prostaglandin J2 (PGJ2; 33.4 μg/injection; unilateral injection to the SNpc; once per week for 2 or 4 weeks) induces progressive PD-like pathology and exhibites microglia and astrocyte activation and motor deficits in the rats^[4].

Animal Model:	Sixteen-week-old Sprague Dawley male rats^[4]
Dosage:	33.4 μg/injection
Administration:	Unilateral (right side) injections to the SNpc; once per week for 2 or 4 weeks
Result:	Induced progressive dopaminergic neuronal loss in the rat substantia nigra pars compacta (SNpc). Developed parkinsonian-like motor deficits in a progressive manner.

IC 50

hDP: 0.9 nM (Ki); hCRTH2: 6.6 nM (Ki); hEP1: 15.678 μM (Ki); hEP2: 989 nM (Ki); hEP3: 319 nM (Ki); hEP4: 1065 nM (Ki); hFP: 553 nM (Ki); hIP: >25 μM (Ki); hTP: 6426 nM (Ki); Human Endogenous Metabolite

References

[1] D. HAMISH WRIGHT. Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist[J]. British Journal of Pharmacology, 2009, 123 7: 1317-1324. DOI: 10.1038/sj.bjp.0701708
[2] NICOLE SAWYER. Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2[J]. British Journal of Pharmacology, 2009, 137 8: 1163-1172. DOI: 10.1038/sj.bjp.0704973
[3] TENEKA JEAN-LOUIS Maria E F P Patricia Rockwell. Prostaglandin J2 promotes O-GlcNAcylation raising APP processing by α- and β-secretases: relevance to Alzheimer’s disease[J]. Neurobiology of Aging, 2018, 62: Pages 130-145. DOI: 10.1016/j.neurobiolaging.2017.10.009
[4] MARIA E. FIGUEIREDO-PEREIRA John B Chuhyon Corwin. Prostaglandin J2: a potential target for halting inflammation-induced neurodegeneration[J]. Annals of the New York Academy of Sciences, 2016, 1363 1: 125-137. DOI: 10.1111/nyas.12987
[5] CHUHYON CORWIN. Prostaglandin D2/J2 signaling pathway in a rat model of neuroinflammation displaying progressive parkinsonian-like pathology: potential novel therapeutic targets.[J]. Journal of Neuroinflammation, 2018: 272. DOI: 10.1186/s12974-018-1305-3
[6] ABHITA MALAVIYA Paul W S. Synergistic Antiproliferative Effects of Combined γ -Tocotrienol and PPAR γ Antagonist Treatment Are Mediated through PPAR γ -Independent Mechanisms in Breast Cancer Cells.[J]. PPAR Research, 2014: 439146. DOI: 10.1155/2014/439146

PROSTAGLANDIN J2 Supplier

Related Product Information

Send Inquriy